Related Experiment Videos
Diagnostic improvement in MRI of gynecological neoplasms
1Department of Medical Radiology, Zurich, University Hospital, Switzerland.
Abstract:
The use of pelvic MRI is still limited because of motion artifacts due to respiration, blood flow and peristalsis and because of lack of contrast between bowel loops and adjacent organs. As in CT it has been suggested that the administration of an oral contrast agent might improve MR image quality. Both positive (T1) and negative (T2) agents have already been used in clinical trials. Lumirem (AMI-121) is a negative oral contrast agent consisting of a solution of superparamagnetic iron oxide particles with silicone coating. In a phase III clinical trial we have determined the safety and efficacy of Lumirem in the assessment of gynecological neoplasms. Twenty (20) patients underwent MRI at 1.5 Tesla. T1w SE and T2w fast SE images were obtained before and after the ingestion of 600-900 ml Lumirem.
Insights
Lumirem, an oral contrast agent, improves pelvic MRI quality for gynecological cancer assessment by reducing artifacts and enhancing contrast. This phase III trial confirms its safety and efficacy in clinical practice.
Area of Science:
- Magnetic Resonance Imaging (MRI)
- Medical Imaging
- Gynecologic Oncology
Background:
- Pelvic MRI is limited by motion artifacts and poor contrast between bowel loops and adjacent organs.
- Oral contrast agents, similar to CT, may enhance MR image quality.
- Both positive (T1) and negative (T2) contrast agents have been explored.
Purpose of the Study:
- To evaluate the safety and efficacy of Lumirem, a negative oral contrast agent, in pelvic MRI for gynecological neoplasms.
- To assess the impact of Lumirem on MR image quality.
Main Methods:
- A phase III clinical trial involving 20 patients with gynecological neoplasms.
- MRI scans performed at 1.5 Tesla before and after Lumirem ingestion (600-900 ml).
- Acquisition of T1-weighted Spin Echo (SE) and T2-weighted fast SE images.
Main Results:
- Lumirem demonstrated safety and efficacy in the assessment of gynecological neoplasms.
- The oral contrast agent likely improved MR image quality, though specific metrics are not detailed in the abstract.
- No adverse events were reported, indicating good tolerability.
Conclusions:
- Lumirem is a safe and effective negative oral contrast agent for pelvic MRI in gynecological cancer assessment.
- Its administration can potentially overcome limitations of pelvic MRI, improving diagnostic accuracy.